The firm had posted a net profit of Rs 650 crore for the same period year ago, Torrent Pharmaceuticals said in a filing to BSE.
Consolidated total income from operations also declined to Rs 1,545 crore for the quarter under consideration as against Rs 1,947 crore for the corresponding period of the previous fiscal.
The company's formulation business in India recorded revenues of Rs 504 crore for the first quarter of FY16-17 as against Rs 491 crore for the same period last fiscal.
""Previous period includes exceptional revenues and profits which was primarily on account of the launch of a new product in the US market, which had limited competition," Torrent Pharma said.
Shares of Torrent Pharmaceuticals today closed 3.60 per cent down at Rs 1,409.20 ascrip on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
